This book is the first authoritative and comprehensive volume presenting basic, translational and clinical research demonstrating the importance of primordial, primary and secondary prevention starting in childhood for the reduction of adult cardiovascular diseases. Chapters will various childhood cardiovascular risk factors that predict adult cardiovascular and other health conditions. The book will also cover lessons learned from longitudinal cardiovascular cohorts such as the Bogalusa Heart Study, the Young Finns Study, and the Avon Longitudinal Study of Parents and Children. In addition, the book covers adolescent cohorts from low and middle-income countries.

Primordial Prevention of Cardiovascular Disease will serve as the premier textbook for preventive cardiology across the lifespan and will serve as a valuable resource for physicians, residents, fellows and medical students in cardiology, primary care, and health promotion and disease prevention.

Discusses the importance of primordial, primary and secondary prevention starting in childhood Covers a variety of childhood CV risk factors Presents core lessons from longitudinal cardiovascular cohorts from around the world

Autorentext

Elaine M Urbina, MD, MS, is the Professor Emeritus of Preventive Cardiology at the Cincinnati Children's Hospital Medical Center. Her clinical activities and industry sponsored grants focused on prevention (obesity, hypertension and dyslipidemias). Her research grants concentrated on new non-invasive methods of assessing atherosclerotic CV target organ damage in youth related to CV risk factors especially those that cluster with obesity. She has over 30 years of experience in non-invasive imaging of CV structure and function in large epidemiologic studies such as the Bogalusa Heart Study. She was the PI of a National Institutes of Health grant (NHLBI R01) following the cardiac and vascular effects of obesity and type 2 diabetes on adolescents and an American Heart Association grant evaluating the CV effects of hypertension in adolescents.  She is a member of the International Childhood CV Cohorts Consortium that will be following Bogalusa, Muscatine, Young Finns and other cohorts that collected CV risk factor data in children starting over 40 years ago with the participants now entering middle age.   Sarah de Ferranti, MD, MPH, is an Associate Professor of Pediatrics at Harvard Medical School and Chief of the Ambulatory Cardiology Division at Boston Children's Hospital. She divides her time between clinical and implementation research, and caring for patients with preventive cardiology and congenital heart disease. Her research has included epidemiology, nutrition and pharmaceutical clinical trials, and more recently qualitative and modeling projects. Early on, she developed a definition of pediatric metabolic syndrome. Her first prospective research project, “Inflammation in Children at High Risk for Atherosclerotic Disease”, laid the ground work for a nutritional intervention in adolescents with metabolic syndrome supported by an Eleanor and Miles Shore Scholarship, and subsequently by NHLBI through the K23 mechanism, the first feeding study conducted at Boston Children's Hospital, and the first of its kind in overweight adolescents. She is currently MPI of the Boston Children’s Pediatric Heart Network center grant, and is Associate Director of the Departmental T32. Recent work has focused on Familial Hypercholesterolemia - screening, diagnosing and treating in childhood.

Inhalt

Section 1: Evidence for the Importance of Primordial Prevention .- Chapter 1. Pre-conception Health and Future CVD.- Chapter 2. Biological Programming in the Perinatal Period: animal studies.- Chapter 3. Biological Programming in the Perinatal Period: human studies.- Chapter 4. Environmental Factors Increasing Risk for Cardiometabolic Disorders.- Chapter 5. Childhood Factors Predicting Adult Cardiometabolic Risk.- Chapter 6. Childhood CV Risk Factors Predicting Adult Sub-clinical Target Organ Damage.- Chapter 7. Childhood CV Risk Factors Predicting Adolescent and Young Adult Target Organ Damage.- Chapter 8. Childhood CV Risk Factors Predicting Adult CV Events.- Chapter 9. Primordial Prevention in the Young and reduction of CV Risk Factors and Subclinical Disease in Adulthood.- Chapter 10. Lifestyle Interventions to Reduce CV Risk in the Young.- Chapter 11. Pharmacologic Therapy to Prevent CV Disease in High-Risk Youth.- Section 2: Lessons Learned From Longitudinal CV Cohorts .- Chapter 12. Bogalusa Heart Study.- Chapter 13. Young Finns Study.- Chapter 14. Cardiovascular Determinants of Adult Risk.- Chapter 15. Muscatine Heart Study.- Chapter 16. Special Turku Risk factor Intervention Project.- Chapter 17. Coronary Artery Risk Detection in Appalachian Communities.- Chapter 18. National Longitudinal Study of Adolescent to Adult Health.- Chapter 19. Avon Longitudinal Study of Parents and Children.- Chapter 20. Atherosclerosis Risk in Young Adults.- Chapter 21. Generation R.- Chapter 22. Kangwha Study.- Chapter 23. Adolescent Cohorts from Low and Middle-income Countries.- Chapter 24. Synthetic Cohorts.